Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 4/20 | 0.44 |
| ▸ | CMA1 | P23946 | 2/20 | 0.44 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.41 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31727396 | 1.00 | HDAC3 (0.46) | HDAC3AHRCMA1EIF2AK2PDK2 | |
| SCHEMBL2491904 | 0.84 | AHR (0.50) | HDAC3AHRCMA1EIF2AK2PDK2 | |
| SCHEMBL548762 | 0.84 | AHR (0.50) | HDAC3AHRCMA1EIF2AK2PDK2 | |
| SCHEMBL522090 | 0.84 | CA9 (0.54) | CA9KIF11 | |
| SCHEMBL15929644 | 0.78 | GRIA1 (0.47) | AHRCMA1EIF2AK2PDK2GRIA1 | |
| SCHEMBL31727129 | 0.78 | AHR (0.53) | AHRCMA1EIF2AK2PDK2GRIA1 | |
| SCHEMBL1847559 | 0.78 | AHR (0.53) | HDAC3AHRCMA1EIF2AK2PDK2 | |
| SCHEMBL30224280 | 0.78 | AHR (0.53) | HDAC3AHRCMA1EIF2AK2PDK2 | |
| SCHEMBL153860 | 0.78 | AHR (0.53) | HDAC3AHRCMA1EIF2AK2PDK2 | |
| SCHEMBL222332 | 0.78 | AHR (0.53) | AHRCMA1EIF2AK2PDK2GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150287-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | HANGZHOU APELOA MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| EP-4282865-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| CN-116997550-A | N- (benzoyl) -phenylalanine compounds, pharmaceutical compositions containing same and application thereof | 杭州普洛药物研究院有限公司 | 2023-11-03 | — | — | CN | disclosed |
| WO-2023078207-A1 | 6-POSITION-SUBSTITUTED INDOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 南京中医药大学 | 2023-05-11 | — | — | WO | disclosed |
| CN-114853659-A | N- (benzoyl) -phenylalanine compounds, pharmaceutical compositions containing same, and uses thereof | 普洛药业股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | disclosed |
| US-8697692-B2 | Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2014-04-15 | — | — | US | disclosed |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-11-14 | — | — | US | disclosed |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-11-14 | — | — | US | disclosed |
| EP-1973910-A1 | PYRROLO Ý3,2-C¨PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2008-10-01 | — | — | EP | disclosed |
| WO-2008100457-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
| WO-2007085188-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2007-08-02 | — | — | WO | disclosed |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
| WO-2007024944-A1 | IMIDAZOLE DERIVATIVES AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| US-5252536-A | Substituted indolinones useful as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0549892-A1 | Substituted indolinones useful as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1993-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150287-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | ITGB7, ITGB4, ITGA4 | HDAC3 1565/4885AHR 1172/4885CMA1 1058/4885 |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | PRKACA, PACSIN2, PRKACB | HDAC3 2871/4885AHR 4803/4885CMA1 800/4885 |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | HDAC3 2055/4885AHR 414/4885CMA1 1182/4885 |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | HDAC3 2055/4885AHR 414/4885CMA1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.